Long-acting somatostatin analogue that suppresses GH, IGF-1, glucagon, and insulin secretion; FDA-approved for acromegaly and carcinoid tumors, but explored in biohacking circles for IGF-1 modulation and cancer-adjacent protocols.
~1.7-1.9 hours (immediate-release); LAR depot effective ~4 weeks
Common dose range
50-200 mcg SC 3x/day (immediate-release); 10-30 mg/month IM (LAR)
Typical cycle length
Per clinical indication; not established for non-clinical use
BioHack Track models Octreotide (Sandostatin) at a half-life of 1.8 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.
No approved product cited
No FDA-approved product for this compound is cited on this page, and no approved human dose is quoted. Treat the range below as research and community practice rather than a prescribed dose.
Reconstitution
Immediate-release: supplied in pre-filled syringes. LAR: requires reconstitution with provided diluent at clinic.
Storage
Refrigerate.
Cautions
Prescription medication. Suppresses multiple hormones including thyroid and GI hormones, causing GI side effects, gallstones, and blood glucose dysregulation. Not for self-administration outside clinical guidance.
Track Octreotide (Sandostatin) in BioHack Track. Half-life, dose range and route come
pre-filled from this library — log a dose and the app counts your vial down, models what is
in your system, and puts it on the same chart as your labs and body composition.
Evidence Check asks 10 questions about every compound. For Octreotide (Sandostatin) it can answer 2 of them, from the papers we hold — graded by how strong the study design is, not by whether the findings are flattering. These are the same verdicts the app gives.
Strongest EvidenceCognition
Meta-analyses or systematic reviews exist — the highest grade of evidence there is, whatever they conclude. Read them.
68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-AnalysisMeta-Analysis · J Nucl Med · 2016 · PMID 26769864
[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 studyRandomized Controlled Trial · Lancet · 2024 · PMID 38851203
(177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialRandomized Controlled Trial · Lancet Oncol · 2021 · PMID 34793718
Strongest EvidenceLongevity
Meta-analyses or systematic reviews exist — the highest grade of evidence there is, whatever they conclude. Read them.
68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-AnalysisMeta-Analysis · J Nucl Med · 2016 · PMID 26769864
Research references only. Not medical advice, and not a recommendation to take anything.
Look up the research
These open a search of each database for Octreotide (Sandostatin) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
12 papers naming Octreotide (Sandostatin) in the title, drawn from PubMed and limited to reviews, meta-analyses and trials. Each was checked against PubMed’s own record for its title, journal and year. This is a starting point, not an evidence review — nothing here is offered as support for the dose range above, and the list is not exhaustive. See the editorial policy.
The half-life, route and dose range on this page are compiled from published
pharmacokinetic literature, manufacturer and product monographs where one exists, and the
ranges commonly reported in clinical and research use. They are kept as a range
rather than a single figure because that is what the sources actually support — a
half-life varies with route, formulation and the person.
These are not citations, and this page is not a review of the evidence. Where a
number matters to you, follow the database links above and read the source. We say so
plainly rather than dressing a compiled reference up as one.
Nothing on this page has been reviewed by a named clinician. It is a reference for
people already tracking a protocol, not a recommendation to start one.
Published by Creative Images LLC ·
Last updated ·
Corrections: support
General reference compiled for use
inside the app, not medical advice and not a recommendation to take anything. Dose ranges are
what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.